COMMUNIQUÉS West-GlobeNewswire

Leading Independent Proxy Advisory Firm ISS Recommends Aptose Biosciences Shareholders Vote “FOR” Proposed Plan of Arrangement with Hanmi Pharmaceutical
19/03/2026
SAN DIEGO and TORONTO, March 19, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“ Aptose ” or the “ Company ”) (TSX: APS; OTC: APTOF) today announced that Institutional Shareholder Services (“ISS”), a leading [...]
Curia Expands Glasgow Manufacturing Capacity and Enhances Cell Line Development Platform
19/03/2026
ALBANY, N.Y., March 19, 2026 (GLOBE NEWSWIRE) -- Curia, a leading contract research, development and manufacturing organization (CDMO), today announced progress on the expansion at its Glasgow, UK sterile drug product [...]
Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights
19/03/2026
Additional data analyses from Orbit and Cosmic Phase 3 studies of setrusumab (UX143) in osteogenesis imperfecta ongoing Cash of $41.0 million as of December 31, 2025, expected to provide runway into mid-2027 LONDON, [...]
Passing of Genmab A/S’ Annual General Meeting
19/03/2026
Company Announcement At Genmab A/S’ Annual General Meeting held today March 19, 2026, the Annual Report for 2025 was approved Discharge was given to the Board of Directors and the Executive Management and the year’s [...]
Persica Pharmaceutical’s PP353 Phase 1b Data Selected for Oral Presentation at the American Society of Interventional Pain Physicians (ASIPP) 2026 Annual Meeting
19/03/2026
ASIPP presentation follows publication of positive data from PP353 Phase 1b Modic Trial in The Lancet’s eClinicalMedicine London, UK, 19 March 2026 - Persica Pharmaceuticals Limited (Persica), a clinical stage [...]
BOOST Pharma Appoints Leading Biopharma Leader Elaine Jones as Chair
19/03/2026
Seasoned life science investor, executive and board leader to support next phase of growth as BOOST Pharma advances BT-101, a promising and potentially disease-modifying therapy for osteogenesis imperfecta STOCKHOLM, [...]
Roquette’s 2025 results show the resilience of its expanded portfolio in a very difficult market environment
19/03/2026
Roquette’s 2025 results show the resilience of its expanded portfolio in a very difficult market environment The Group’s strategy and recent acquisitions enable upselling to higher-value markets +8% turnover growth to € [...]
Les résultats 2025 de Roquette illustrent la résilience d’un portefeuille élargi, dans un contexte de marché très exigeant
19/03/2026
Les résultats 2025 de Roquette illustrent la résilience d’un portefeuille élargi, dans un contexte de marché très exigeant La stratégie du Groupe et ses acquisitions récentes lui permettent de monter en gamme sur des [...]
SK pharmteco Reaffirms Three-Business-Unit Strategy, Strengthens Global Gene Therapy Business Unit with Funding Commitment
19/03/2026
RANCHO CORDOVA, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- SK pharmteco today announced a significant funding commitment to support strategic initiatives within its viral vector business, while reaffirming its long-term [...]
Dr. Myung Ju Lee of VIP Plastic Surgery Receives Minister of Health and Welfare Award at Medical Korea 2026
19/03/2026
National honor recognizes Dr. Lee’s leadership in advancing Korea’s global healthcare standards and excellence in facial plastic surgery SEOUL, Korea, March 19, 2026 (GLOBE NEWSWIRE) -- Myung Ju Lee, MD, PhD, founder of [...]
Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering
19/03/2026
CUPERTINO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet [...]
SnoreStop Throat Spray Claims Evaluated: Effective Anti-Snoring Oral Solution with Clinically Proven Ingredients
18/03/2026
A 2026 source-based informational overview of SnoreStop's doctor-developed oral spray formula as described in company materials, cited clinical study references, homeopathic ingredient research context, pricing [...]
Extendicare Announces Proposed Changes to Board of Directors
18/03/2026
MARKHAM, Ontario, March 18, 2026 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today announced that its board of directors (“Board of Directors” or “Board”) has nominated Josh Blair [...]
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
19/03/2026
Based on the Strength of Unprecedented Results from the Positive Phase 1/2 Study in Adults Aged 50 and Older, Vaxcyte Advanced VAX-31 High Dose into Comprehensive Phase 3 Adult Program; Topline Data from the OPUS-1 [...]
2026 MAP Awards presented to 20 organizations for high performance in revenue cycle
18/03/2026
CHICAGO, March 18, 2026 (GLOBE NEWSWIRE) -- The Healthcare Financial Management Association (HFMA) announced the 2026 winners of the MAP Award for High Performance in Revenue Cycle, including three integrated delivery [...]
Alvotech Q4 2025 and Full Year 2025 Financial Results
18/03/2026
A supplemental long ‑ form earnings release providing additional operational details and business update for Q4 2025 and the full year is available at: https://investors.alvotech.com/earnings-calendar The supplemental [...]
Alvotech Q4 2025 and Full Year 2025 Financial Results
18/03/2026
REYKJAVIK, Iceland, March 18, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ US: ALVO, ICELAND: ALVO, STOCKHOLM: ALVO SDB) Financial Highlights A supplemental long ‑ form earnings release providing additional operational [...]
Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results
18/03/2026
Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses Research published in Nature Medicine [...]
ADR Ratio Change
18/03/2026
March 18, 2026 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) ADR Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative [...]

Pages